Literature DB >> 27542962

Active case finding for carbapenemase-producing Enterobacteriaceae in a teaching hospital: prevalence and risk factors for colonization.

K Poole1, R George2, V Decraene3, K Shankar4, J Cawthorne2, N Savage5, W Welfare6, A Dodgson7.   

Abstract

BACKGROUND: Over the past decade, the prevalence of carbapenemase-producing Enterobacteriaceae (CPE) has increased. Whilst basic infection prevention and control practices reduce the risk of transmission, cases of unrecognized carriage pose a potential risk of transmission. AIM: To estimate the prevalence of CPE and explore risk factors associated with colonization within a large teaching hospital with an established CPE outbreak.
METHODS: All inpatients that had not previously tested positive for CPE were offered testing. Demographic and hospital episode data were also collected, together with antibiotic and proton pump inhibitor (PPI) use in the preceding 24h.
FINDINGS: This study identified 70 CPE-positive cases (26 newly identified and 44 previously known) and 592 CPE-negative cases, giving a combined prevalence of 11% [95% confidence interval (CI) 8-13]. Medication (antibiotic and PPI use), previous admission, ethnicity and length of stay were assessed as risk factors for colonization, and none were found to be independently associated with CPE colonization. Using logistic regression, age [odds ratio (OR) 1.03, 95% CI 1.01-1.07] and antibiotic use (OR 2.55, 95% CI 1.08-6.03) were the only risk factors significantly associated with CPE colonization.
CONCLUSION: This study has added to the evidence base by estimating the prevalence of CPE among inpatients in an acute hospital with an established CPE outbreak. A case-finding exercise was feasible and identified a number of new cases. Despite a small sample size, increasing age and prescription of an antibiotic on the day of testing were significantly associated with CPE colonization. Crown
Copyright © 2016. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Carbapenemase; Enterobacteriaceae; Multiple antibacterial drug resistance; Prevalence; Risk factors

Mesh:

Substances:

Year:  2016        PMID: 27542962     DOI: 10.1016/j.jhin.2016.06.019

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  6 in total

Review 1.  Chemical disinfectants: Controversies regarding their use in low risk healthcare environments (part 1).

Authors:  Evonne T Curran; Martyn Wilkinson; Tina Bradley
Journal:  J Infect Prev       Date:  2019-03-05

2.  A Systematic Review and Meta-analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae.

Authors:  Karlijn van Loon; Anne F Voor In 't Holt; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

3.  Audit of the management of patients at high risk of carbapenemase-producing enterobacteriaceae (CPE): Are we ready?

Authors:  Lasantha Ratnayake; Amy Harris; Doreen Ko; Linda Hawtin
Journal:  J Infect Prev       Date:  2017-05-23

4.  Fast and expensive (PCR) or cheap and slow (culture)? A mathematical modelling study to explore screening for carbapenem resistance in UK hospitals.

Authors:  Gwenan M Knight; Eleonora Dyakova; Siddharth Mookerjee; Frances Davies; Eimear T Brannigan; Jonathan A Otter; Alison H Holmes
Journal:  BMC Med       Date:  2018-08-16       Impact factor: 8.775

5.  The acceptability of screening for Carbapenemase Producing Enterobacteriaceae (CPE): cross-sectional survey of nursing staff and the general publics' perceptions.

Authors:  Kay Currie; Caroline King; Kareena McAloney-Kocaman; Nicola J Roberts; Jennifer MacDonald; Adele Dickson; Shona Cairns; Nitish Khanna; Paul Flowers; Jacqui Reilly; Lesley Price
Journal:  Antimicrob Resist Infect Control       Date:  2018-11-23       Impact factor: 4.887

6.  Infection control and risk factors for acquisition of carbapenemase-producing enterobacteriaceae. A 5 year (2011-2016) case-control study.

Authors:  Luigi Segagni Lusignani; Elisabeth Presterl; Beata Zatorska; Miriam Van den Nest; Magda Diab-Elschahawi
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-17       Impact factor: 4.887

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.